Related Experiment Video
Updated: May 27, 2026
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial
Douglas L Boggs1, Deanna L Kelly, Robert P McMahon
1VA Connecticut Healthcare System, West Haven, CT, USA.
Objective:
To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia.
Methods:
Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study.
Results:
In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects.
Conclusions:
Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.
